---
title: Bill Gates investment strategy in vaccine stocks
videoId: cwpGBCjpJiU
---

From: [[artedeinvertir]] <br/> 

Bill Gates, one of the world's wealthiest and most influential individuals <a class="yt-timestamp" data-t="00:00:03">[00:00:03]</a>, appears to be preparing for a potential new crisis <a class="yt-timestamp" data-t="00:00:07">[00:00:07]</a> by accumulating stocks in companies that produce vaccines <a class="yt-timestamp" data-t="00:00:11">[00:00:11]</a>. This shift represents a radical change in his [[bill_gates_investment_strategy_and_portfolio | investment strategy]] <a class="yt-timestamp" data-t="00:00:23">[00:00:23]</a>, with the reasons behind this move potentially being concerning <a class="yt-timestamp" data-t="00:00:25">[00:00:25]</a>.

## Bill Gates' Influence and Past Predictions

Gates played a significant role during the recent global crisis <a class="yt-timestamp" data-t="00:00:49">[00:00:49]</a>. He previously warned about the high likelihood of a pandemic similar to the one experienced <a class="yt-timestamp" data-t="00:00:52">[00:00:52]</a> and noted that the world was unprepared <a class="yt-timestamp" data-t="00:00:56">[00:00:56]</a>. His extensive knowledge of the biotechnology sector also enabled him to predict which company would first develop a successful vaccine <a class="yt-timestamp" data-t="00:01:03">[00:01:03]</a>.

Having built a fortune exceeding $100 billion from scratch <a class="yt-timestamp" data-t="00:01:07">[00:01:07]</a>, Gates is widely recognized for co-founding Microsoft <a class="yt-timestamp" data-t="00:01:16">[00:01:16]</a>. Less known is his excellent track record in investment <a class="yt-timestamp" data-t="00:01:20">[00:01:20]</a>; his movements and statements are closely followed by millions of investors globally due to his accurate vision for the future of the economy and stocks <a class="yt-timestamp" data-t="00:01:27">[00:01:27]</a>.

## Radical Shift in Investment Strategy

Recent public disclosures of his [[bill_gates_investment_strategy_and_portfolio | investment portfolio]] reveal a significant change <a class="yt-timestamp" data-t="00:01:34">[00:01:34]</a>. It appears he is preparing for a crisis akin to the one in 2020 <a class="yt-timestamp" data-t="00:01:38">[00:01:38]</a>. This [[bill_gates_investment_strategy_and_portfolio_changes | investment strategy]] has radically shifted, with 70% of his investments now concentrated in just three companies that produce vaccines <a class="yt-timestamp" data-t="00:01:43">[00:01:43]</a>. Many investors are questioning whether this new [[bill_gates_investment_strategy_and_portfolio | investment strategy]] reflects a negative outlook on the evolution of the crisis that began in 2020 <a class="yt-timestamp" data-t="00:01:57">[00:01:57]</a>.

### Transparency in Investment Movements

In the United States, stock market transparency rules require institutional investors with over $100 million in assets to periodically report their stock purchases and sales to the American regulator <a class="yt-timestamp" data-t="00:02:13">[00:02:13]</a>. This allows insight into Bill Gates' vision for the economy and stock market, which is often considered more valuable than his public statements <a class="yt-timestamp" data-t="00:02:26">[00:02:26]</a>.

Bill Gates utilizes two primary investment vehicles <a class="yt-timestamp" data-t="00:02:36">[00:02:36]</a>:
1.  A fund for more traditional and safer shares <a class="yt-timestamp" data-t="00:02:38">[00:02:38]</a>.
2.  The portfolio of the Bill and Melinda Gates Foundation <a class="yt-timestamp" data-t="00:02:43">[00:02:43]</a>, which is the focus of this analysis due to its new investment strategy <a class="yt-timestamp" data-t="00:02:46">[00:02:46]</a>.

## Focus on Second-Generation Vaccines

Within the Gates Foundation portfolio, three [[top_stocks_in_bill_gates_portfolio | stocks]]—BioNTech, CureVac, and Vir Biotechnology—account for over 70% of his total investment <a class="yt-timestamp" data-t="00:02:53">[00:03:00]</a>. These companies are not randomly chosen; they are leading the development of "second-generation vaccines," which are expected to be more sophisticated and effective against the ongoing problem <a class="yt-timestamp" data-t="00:03:03">[00:03:14]</a>.

In a CNN interview, Bill Gates highlighted the inadequacy of vaccine distribution to poorer countries <a class="yt-timestamp" data-t="00:03:27">[00:03:37]</a>. He warned that variants would return to wealthier nations because the problem wasn't addressed quickly enough <a class="yt-timestamp" data-t="00:03:40">[00:03:47]</a>. This situation necessitates the development of these second-generation vaccines, which aligns with his current portfolio focus <a class="yt-timestamp" data-t="00:03:48">[00:03:54]</a>.

### Bill Gates' Stated Reason for Investment

In an interview with CNBC, Bill Gates explicitly stated his primary reason for investing heavily in this sector:
> "We will only return to normal when we have not the first generation of vaccines but the next generation of vaccines <a class="yt-timestamp" data-t="00:08:58">[00:09:03]</a>. The good news is that there are a large number of companies working to achieve this second generation <a class="yt-timestamp" data-t="00:09:05">[00:09:07]</a>."

These statements, coupled with his recent portfolio movements, provide insight into which companies he believes are best positioned to develop the next generation of vaccines <a class="yt-timestamp" data-t="00:09:09">[00:09:18]</a>.

## Risk and Reward in Biotechnology Investments

Investing in biotechnology companies during their development phase is highly risky and volatile <a class="yt-timestamp" data-t="00:04:03">[00:04:04]</a>, requiring a high level of knowledge to succeed, as Bill Gates appears to possess <a class="yt-timestamp" data-t="00:04:06">[00:04:10]</a>. The number of failed clinical trials is significant <a class="yt-timestamp" data-t="00:04:11">[00:04:12]</a>. However, successful ventures can yield substantial financial rewards <a class="yt-timestamp" data-t="00:04:14">[00:04:16]</a>.

For instance:
*   **BioNTech**: In collaboration with Pfizer, BioNTech was the first to develop an effective vaccine <a class="yt-timestamp" data-t="00:04:19">[00:04:22]</a>. Even after announcing satisfactory clinical trials and reduced risk, its shares surged from $90 to over $350 <a class="yt-timestamp" data-t="00:04:25">[00:04:36]</a>.
*   **Moderna**: As a leading company in vaccine development, Moderna's shares rose from $70 to over $400 in less than 12 months <a class="yt-timestamp" data-t="00:04:38">[00:04:47]</a>.

These examples illustrate the potential for high returns when biotechnology companies succeed in their clinical trials and product development <a class="yt-timestamp" data-t="00:04:14">[00:04:16]</a>.

## [[analysis_of_bill_gates_favorite_vaccine_stocks | Analysis of Bill Gates' Favorite Vaccine Stocks]]

### BioNTech (BNTX)

*   **Ticker**: BNTX <a class="yt-timestamp" data-t="00:05:15">[00:05:15]</a>
*   **Price (at time of transcript)**: $360 per share <a class="yt-timestamp" data-t="00:05:18">[00:05:18]</a>
*   **Origin**: German company <a class="yt-timestamp" data-t="00:05:29">[00:05:29]</a>
*   **Investment Start**: Late 2019, six months before the crisis <a class="yt-timestamp" data-t="00:05:22">[00:05:26]</a>.
*   **Initial Investment**: $50 million <a class="yt-timestamp" data-t="00:05:28">[00:05:29]</a>.
*   **Current Valuation (at time of transcript)**: Over $200 million <a class="yt-timestamp" data-t="00:05:29">[00:05:31]</a>.
*   **Significance**: BioNTech, with Pfizer, was the first to launch an effective vaccine <a class="yt-timestamp" data-t="00:05:33">[00:05:36]</a>. The company anticipates a demand for one million doses per year from 2022 onwards, suggesting this could become a recurrent business <a class="yt-timestamp" data-t="00:05:43">[00:05:51]</a>.
*   **Financials**: Estimated earnings of over $37 per share for the year <a class="yt-timestamp" data-t="00:06:00">[00:06:04]</a>, trading below 10 times earnings <a class="yt-timestamp" data-t="00:06:06">[00:06:07]</a>. If the business proves recurrent, shares could double <a class="yt-timestamp" data-t="00:06:12">[00:06:16]</a>; success in new clinical trials could further increase potential <a class="yt-timestamp" data-t="00:06:21">[00:06:24]</a>.

### CureVac (CVAC)

*   **Ticker**: CVAC <a class="yt-timestamp" data-t="00:06:34">[00:06:34]</a>
*   **Price (at time of transcript)**: $70 per share <a class="yt-timestamp" data-t="00:06:37">[00:06:37]</a>
*   **Origin**: German company <a class="yt-timestamp" data-t="00:06:29">[00:06:30]</a>
*   **Investment Start**: 2015 <a class="yt-timestamp" data-t="00:06:41">[00:06:43]</a>.
*   **Initial Investment**: $50 million <a class="yt-timestamp" data-t="00:06:43">[00:06:46]</a>.
*   **Current Valuation (at time of transcript)**: Over $230 million <a class="yt-timestamp" data-t="00:06:46">[00:06:50]</a>.
*   **Significance**: CureVac collaborates with major companies like GlaxoSmithKline on second-generation vaccines <a class="yt-timestamp" data-t="00:06:53">[00:07:01]</a>.
*   **Risk**: This is a more speculative and volatile investment than BioNTech <a class="yt-timestamp" data-t="00:07:03">[00:07:05]</a>. CureVac is in the development phase, not yet profitable, and heavily reliant on the success of its clinical trials <a class="yt-timestamp" data-t="00:07:07">[00:07:13]</a>. Success in this sector requires a very high level of knowledge <a class="yt-timestamp" data-t="00:07:16">[00:07:17]</a>.

### Vir Biotechnology (VIR)

*   **Ticker**: VIR <a class="yt-timestamp" data-t="00:07:41">[00:07:41]</a>
*   **Price (at time of transcript)**: $48 per share <a class="yt-timestamp" data-t="00:07:44">[00:07:44]</a>
*   **Investment Start**: 2019 <a class="yt-timestamp" data-t="00:07:48">[00:07:50]</a>.
*   **Significance**: This highly innovative company is developing an effective solution against multiple variants, including the Delta variant, with over 82% effectiveness <a class="yt-timestamp" data-t="00:07:52">[00:08:01]</a>.
*   **Unique Approach**: Vir Biotechnology is developing a new, inhaled method of vaccine application, potentially making it easier to administer and increasing public participation <a class="yt-timestamp" data-t="00:08:07">[00:08:17]</a>.
*   **Risk**: Like CureVac, Vir Biotechnology is in the development phase and not yet profitable <a class="yt-timestamp" data-t="00:08:21">[00:08:23]</a>, making it a highly speculative and risky action with potentially high rewards <a class="yt-timestamp" data-t="00:08:25">[00:08:29]</a>.

## Conclusion

Bill Gates' recent [[bill_gates_investing_strategies | investment strategies]], particularly his strong focus on vaccine-producing companies, highlights his belief in the necessity of next-generation vaccines to return to normalcy <a class="yt-timestamp" data-t="00:08:58">[00:09:07]</a>. While investing in developmental biotechnology firms carries high risk, successful outcomes can generate substantial returns for shareholders <a class="yt-timestamp" data-t="00:09:23">[00:09:27]</a>. This strategic shift provides a clear indication of the companies he believes are best positioned to lead this crucial development <a class="yt-timestamp" data-t="00:09:13">[00:09:18]</a>.

For more information on Bill Gates' overall portfolio, refer to the video titled "Bill Gates' entire investment portfolio" <a class="yt-timestamp" data-t="00:09:30">[00:09:35]</a>.